Rahul Banerjee, MD, FACP
@RahulBanerjeeMD
Asst Professor @UWMedicine @fredhutch. Goals: improve pt experience in myeloma #MMsm: ⬇️ dex, ⬆️ time at home, 📱-based wellness. COI: https://coi.asco.org/share/VU2-FHC3/Rahul%20Banerjee
Grateful to @BloodJournal, co-authors, and @SWOG for making this #downwithdex piece possible! Dex 40mg weekly in #MMsm induction: 1️⃣ Not practical even for trial-enrolled patients 2️⃣ Does not improve PFS vs ⬇️ dex Twitter 🧵 once I’m back from #IMS24! ashpublications.org/blood/article/…
#Myeloma Paper of the Day: Cool paper from @RahulBanerjeeMD showing analysis of S0777 and S1211 @SWOG trial data that lowering the dose of dex during induction therapy did not have an impact on long-term outcomes like PFS & OS: pubmed.ncbi.nlm.nih.gov/39321347/. #mmsm
We are proud to share a remarkable outcome at Roswell Park Comprehensive Cancer Center: 100% of patients who underwent allogeneic transplant in 2024 reached six-month survival. I never thought we would ever see such a statistic in our field. roswellpark.org/newsroom/20250…
Fantastic! Congratulations. Kindly convey our regards to Dr. Chandramouli- Asian Myeloma Network, Singapore. @UdayYanamandra @DrPMPGI @VincentRK @NikhilMunshiMD @RahulBanerjeeMD @MirghSumeet @bagalbp @lingarajnayak @Gurksagoo @nikhil91sjmc #mmsm🌿🌏
Excited to be attending this academic feast on #myeloma at the IMF Asian myeloma network masterclass in Singapore Gratitude to @UdayYanamandra and @IndMyAcGp for this wonderful opportunity
Excited to be attending this academic feast on #myeloma at the IMF Asian myeloma network masterclass in Singapore Gratitude to @UdayYanamandra and @IndMyAcGp for this wonderful opportunity
Real important to use IVIG with BsAb therapy in #mmsm @RahulBanerjeeMD
1/ Our call to action is out in @BloodAdvances! Title speaks for itself. Given concerningly high infection risk with bsAbs in myeloma #MMsm, IVIG/SCIG should be started regardless of any IgG threshold. Global authors & global audience, including insurance & healthcare funders.
Now in @JCO_ASCO: ASCO & FDA authors discuss strategies to move away from MTD in oncology 👏 Very relevant to myeloma #MMsm! RW data not mentioned at all, likely for scope - IMO, RW data remain key to optimizing dosing for RW patients after approval. ascopubs.org/doi/full/10.12…
Ph1 AMG 420 dose expansion, just published in Leuk Lymphoma. How far the idea of T-cell redirection in myeloma has advanced based on this now-shelved drug… now 4 approved bsAbs! Congrats @myelomatips @HangQuach1 et al. Last paragraph had me like 🥹 🫡 tandfonline.com/doi/10.1080/10…
The European Union approves Sarclisa (isatuximab-irfc) to be used "in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for newly diagnosed multiple myeloma (NDMM) patients eligible for autologous stem cell transplant." Learn more at myeloma.org/node/11803
The @EMA_News's CHMP has issued positive qualification advice to the novel biomarker procedure application regarding the use of MRD–CR as an early end point for clinical trials to support conditional market approval of treatments for patients with #MultipleMyeloma. #MMSM
Quadruplets are the new standard of induction in myeloma regardless of transplant eligibility
🚨 NEWS 🚨 @EU_Commission has approved isatuximab in combination with bortezomib, lenalidomide, and dexamethasone (Isa-VRd) for the treatment of transplant-eligible newly diagnosed #MultipleMyeloma, based on data from the phase III GMMG-HD7 trial. Learn more:…
🚨 NEWS 🚨 @EU_Commission has approved isatuximab in combination with bortezomib, lenalidomide, and dexamethasone (Isa-VRd) for the treatment of transplant-eligible newly diagnosed #MultipleMyeloma, based on data from the phase III GMMG-HD7 trial. Learn more:…
Important: Belantamab (Blenrep) approved in Canada and Europe for relapsed myeloma. Belantamab is an important addition to the treatments we have. Despite the negative ODAC vote and concerns about dosing and corneal toxicity, I hope it is approved in the US as well.
✨ From spontaneous hallway chats to unforgettable sessions, every photo tells a story. 📷 What’s your favorite IMS memory? Share it in the comments! Ready to make more memories? Register here: [rb.gy/139j28] #IMSThroughTheYears #IMS25
BREAKING NEWS: EU approves belantamab mafodotin (Blenrep®) combinations for relapsed/refractory #myeloma patients! Two new treatment options approved based on positive DREAMM-7 & DREAMM-8 trials showing extended progression-free survival. mpeurope.org/the-european-c… #Blenrep
Amazing work led by @RahulBanerjeeMD !
1/ Our call to action is out in @BloodAdvances! Title speaks for itself. Given concerningly high infection risk with bsAbs in myeloma #MMsm, IVIG/SCIG should be started regardless of any IgG threshold. Global authors & global audience, including insurance & healthcare funders.
Love this so much and cheers to @RahulBanerjeeMD and authors for this paper !!
6/ Link to #MMsm article in @BloodAdvances : ashpublications.org/bloodadvances/…
🧠 Managing Infection Risk in Myeloma: Time to Rethink IgRT? Bispecific antibodies (bsAbs) like teclistamab, elranatamab, talquetamab, and linvoseltamab are transforming multiple myeloma treatment—but bring a persistent risk of infection. 📉 Enter immunoglobulin replacement…